Related Experiment Videos

Electroneurographic investigations of misonidazole polyneuropathy

European Neurology
|January 1, 1979
PubMed

Insights

Misonidazole treatment for malignant tumors can cause early signs of neuropathy, particularly affecting sensory nerves. Electrophysiological tests revealed temporary nerve damage that normalized six months post-therapy.

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Background:

  • Malignant tumors require effective treatment strategies.
  • Radiosensitizers like misonidazole enhance radiation therapy efficacy.
  • Potential neurotoxicity of misonidazole requires investigation.

Purpose of the Study:

  • To investigate the electrophysiological effects of misonidazole on peripheral nerves in cancer patients.
  • To identify early indicators of misonidazole-induced neuropathy.
  • To assess the reversibility of neurotoxic effects.

Main Methods:

  • Electrophysiological studies were conducted on 13 patients with malignant tumors treated with misonidazole (20-29 g total dosage).
  • Nerve conduction velocity (NCV) of peroneal and sural nerves, distal latency, and nerve action potentials (NAP) were assessed.
  • Changes were monitored during and after misonidazole therapy.

Main Results:

  • Early increase in distal latency was observed, indicating subclinical neuropathy.
  • Sensory nerves (sural) showed greater electrophysiological changes than motor nerves.
  • A primary axonal neuropathy was suggested by reduced compound action potentials or NAP in some cases.
  • Electrophysiological parameters normalized approximately 6 months after therapy cessation.

Conclusions:

  • Misonidazole can induce a reversible peripheral neuropathy, primarily affecting sensory nerves.
  • Distal latency is a sensitive marker for detecting subclinical misonidazole-induced neuropathy.
  • Further research into the mechanisms of misonidazole neurotoxicity is warranted.

Related Concept Videos